Successful treatment of intestinal hemorrhage in a Jehovah's Witness patient

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review

“…We recently described a 66-year-old female Jehovah's witness suffering from B-cell chronic lymphocytic leukemia and ulcerative colitis with severe hemorrhage, in whom the use of rFVIIa obviated the need for transfusions. 28 Other authors have reported the use of rFVIIa for bleeding in hemato-oncology pediatric practice. Millar et al 29 described the use of rFVIIa in three boys (one of whom had undergone a haploidentical bone marrow transplant) with life-threatening gastrointestinal hemorrhage.…”

Perioperative Jehovah's Witnesses: a review

“…The optimal dose has not been described, but a commonly used regimen in the literature is 40-65 µg kg −1 , repeated after 15-30 min if there is no improvement. 59 Its successful use has been shown in different haemorrhage scenarios, such as cardiac surgery, 119 postpartum haemorrhage, 120 and intestinal bleeding; 121 however, these are off-label prescriptions. Increasing evidence suggests that it does not improve long-term outcomes and may increase the thromboembolic event rate.…”

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII

“…It has been used for the management of pulmonary hemorrhage [15], massive hemoptysis [16], bleeding from various sites after bone marrow transplantation [17][18][19][20], upper GI bleeding [21][22][23][24], Hickman line insertion [25], intestinal hemorrhage [26], intracranial hemorrhage [27], uterine bleeding [28], femoral artery bleeding after central venous catheter insertion [29], and alltransretinoic acidinduced pulmonary bleeding [30].…”